TOP STORIES

• ORGANIZATION JPMA Launches Website Listing R&D Policies of Members to Help Foster Innovation Ecosystem
  April 9, 2024

• BUSINESS GSK Japan Shooting for 80% Goal for Paid Paternity Leave in 2024
  April 8, 2024

• BUSINESS Kyowa Kirin Hopes Amgen-Partnered Eczema Drug to Rival or Even Eclipse Crysvita in Sales: CEO
  April 5, 2024

• ORGANIZATION PhRMA Hails 2024 Reform, but Says Full Picture Unchanged as 50% of Patented Meds Still Face Cuts
  April 4, 2024

• REGULATORY Opposition Party Head Calls for Rethink of Public Health Coverage in Japan
  April 3, 2024

• COMMENTARY With Honebuto 2024 Looming, Now Is the Time to Revisit Social Security Spending
  April 2, 2024

• BUSINESS New Ono Chief Eager to Go Solo in US, Europe; BTK Med 1st Shield against Opdivo Patent Cliff
  April 1, 2024

• BUSINESS Parexel Helping Japan Address Drug Loss with “Ethnobridging” Studies, PI Still a Hurdle
  March 29, 2024

• REGULATORY MHLW Generic Panel Outlines Plan to Drive Industry Revamp within Specific Time Frame
  March 28, 2024

• REGULATORY Japan Approves Piasky, Beyfortus, Broader Use for Abrysvo, and Lot More
  March 27, 2024

• ORGANIZATION Backed by 12 Pharmas, US Nonprofit’s Cloud Platform Now Up and Running to Streamline Regulatory Submissions
  March 26, 2024

• REGULATORY Chuikyo Agrees to Exempt PD-1/PD-L1, JAK Classes from Spillover Re-Pricing
  March 25, 2024

• REGULATORY Xocova’s Price to Remain Intact after Full Approval, No Change in Clinical Positioning
  March 25, 2024

• REGULATORY Pharma Regulation Panel Wraps Up Debate, Report to Be Finalized Soon
  March 22, 2024

• REGULATORY Japan Resumes Debate on Rx-to-OTC Switch of PPIs after Over 5 Years
  March 22, 2024

• BUSINESS Will Kyowa Kirin’s Eye Drops for nAMD Replace Intraocular Injections? PII Now Underway
  March 21, 2024

• BUSINESS Meiji’s Bivalent COVID Jab Hits Primary Goal in PIII Omicron Trial; New Strains Eyed
  March 21, 2024

• REGULATORY Japan Mulls Simplifying Drug Delisting Process to Help Ensure Stable Supplies
  March 19, 2024

• BUSINESS FY2024 Revision Rates Tallied for Each Firm’s Top 5 Meds; Fuso Logs Price Hike Too on Infusion Products
  March 18, 2024

• BUSINESS Sumitomo Offloads Entire Ulotaront Rights to Otsuka for Strategic Priorities
  March 18, 2024

ページ

• « 先頭
• ‹ Prev
• …
• 29
• 30
• 31
• 32
• 33
• 34
• 35
• 36
• 37
• …
• Next ›
• 最終 »